Bio Blast Pharma Ltd. (NASDAQ:ORPN) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $17.00 for the company and are forecasting that the company will post ($0.26) earnings per share for the current quarter, according to Zacks. Zacks has also given Bio Blast Pharma an industry rank of 81 out of 265 based on the ratings given to related companies.
A number of research firms have commented on ORPN. Zacks Investment Research raised shares of Bio Blast Pharma from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Tuesday, September 13th. Roth Capital set a $15.00 price objective on shares of Bio Blast Pharma and gave the stock a “buy” rating in a report on Monday, October 24th.
Shares of Bio Blast Pharma (NASDAQ:ORPN) opened at 1.53 on Monday. The firm’s market capitalization is $25.08 million. The company has a 50-day moving average of $1.54 and a 200-day moving average of $1.70. Bio Blast Pharma has a 52 week low of $1.36 and a 52 week high of $7.95.
Bio Blast Pharma (NASDAQ:ORPN) last released its quarterly earnings data on Thursday, August 25th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. During the same quarter last year, the company posted ($0.26) earnings per share. On average, equities analysts forecast that Bio Blast Pharma will post ($0.95) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Bio Blast Pharma stock. Knoll Capital Management LP purchased a new stake in shares of Bio Blast Pharma Ltd. (NASDAQ:ORPN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 250,970 shares of the biopharmaceutical company’s stock, valued at approximately $424,000. Bio Blast Pharma accounts for approximately 0.7% of Knoll Capital Management LP’s investment portfolio, making the stock its 15th largest position. Knoll Capital Management LP owned approximately 1.53% of Bio Blast Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 7.86% of the company’s stock.
Bio Blast Pharma Company Profile
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.